AbCellera Biologics (ABCL) to Release Earnings on Monday

AbCellera Biologics (NASDAQ:ABCL) is expected to be releasing its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $5.6980 million for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 5:00 PM ET.

AbCellera Biologics (NASDAQ:ABCL) last issued its earnings results on Tuesday, February 24th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.15. The firm had revenue of $44.85 million for the quarter, compared to the consensus estimate of $6.31 million. AbCellera Biologics had a negative net margin of 198.37% and a negative return on equity of 15.05%. On average, analysts expect AbCellera Biologics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AbCellera Biologics Stock Up 2.0%

ABCL traded up $0.09 during mid-day trading on Monday, reaching $4.52. 3,933,681 shares of the company traded hands, compared to its average volume of 4,334,695. AbCellera Biologics has a 52-week low of $1.94 and a 52-week high of $6.51. The stock has a market capitalization of $1.38 billion, a P/E ratio of -9.19 and a beta of 1.02. The company’s fifty day moving average price is $3.60 and its 200-day moving average price is $3.86.

Institutional Investors Weigh In On AbCellera Biologics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. increased its stake in shares of AbCellera Biologics by 27.9% in the fourth quarter. Invesco Ltd. now owns 54,603 shares of the company’s stock worth $187,000 after acquiring an additional 11,914 shares during the period. XTX Topco Ltd acquired a new stake in AbCellera Biologics in the fourth quarter valued at approximately $1,242,000. nVerses Capital LLC purchased a new position in shares of AbCellera Biologics during the 4th quarter valued at approximately $121,000. Voloridge Investment Management LLC grew its stake in AbCellera Biologics by 170.0% in the 4th quarter. Voloridge Investment Management LLC now owns 695,796 shares of the company’s stock valued at $2,380,000 after acquiring an additional 438,061 shares during the period. Finally, Virtus Investment Advisers LLC increased its holdings in AbCellera Biologics by 103.4% in the 4th quarter. Virtus Investment Advisers LLC now owns 73,488 shares of the company’s stock worth $251,000 after acquiring an additional 37,365 shares in the last quarter. 61.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ABCL. JonesTrading began coverage on AbCellera Biologics in a research report on Friday, April 10th. They set a “buy” rating and a $11.00 price objective on the stock. Wall Street Zen upgraded shares of AbCellera Biologics from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AbCellera Biologics in a research note on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, AbCellera Biologics has an average rating of “Moderate Buy” and a consensus target price of $8.40.

AbCellera Biologics Company Profile

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.